Evidence map›Paper›PMID 34036874›Full record

ArticleEmerging microbes & infections2021

Where are the RNA vaccines for TB?

Xiao-Yong Fan, Douglas Bruce Lowrie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Protective RNA nanovaccines againstFrontiers in immunology · 2023
    Article
  5. Review
  6. Review
  7. Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiao-Yong FanTB Center, Shanghai Emerging and Re-emerging Institute, Shanghai Public Health Clinical Center and Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0001-6654-3559
Douglas Bruce LowrieTB Center, Shanghai Emerging and Re-emerging Institute, Shanghai Public Health Clinical Center and Key Laboratory of Medical Molecular Virology of MOE/MOH, Fudan University, Shanghai, People's Republic of China.ORCID https://orcid.org/0000-0003-2689-9627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A simple mRNA vaccine was shown to protect mice against tuberculosis more than 15 years ago. Like COVID-19, tuberculosis is a respiratory infection killing over a million people per year. It too presents a global emergency. Can the stunning success of RNA vaccination against COVID-19 be replicated for TB?

Indexed as

HumansmRNA VaccinesTuberculosisTuberculosis VaccinesVaccines, SyntheticmRNA VaccinesTuberculosis VaccinesVaccines, SyntheticCOVID-19in vitro transcriptionRNA vaccinationTuberculosisvaccine

Identifiers

PMID34036874
PMCPMC8216257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.